Literature DB >> 14595822

Aberrant profiles of native and oxidized glycoproteins in Alzheimer plasma.

Han-Ling Yu1, Howard M Chertkow, Howard Bergman, Hyman M Schipper.   

Abstract

A proteomic approach was employed to elucidate possible differential expression of native and oxidized glycoproteins using pooled plasma samples derived from ten patients with sporadic Alzheimer's disease (AD) and pooled plasma samples from nine normal elderly control (NEC) subjects. The plasma samples were fractionated by sequential affinity chromatography on heparin-agarose (HepA) and concanavalin A-agarose (ConA) columns followed by separation on one-dimensional and two-dimensional polyacrylamide gels. Carbonylation (oxidation) of proteins was monitored by in-strip derivatization with 2,4-dinitrophenylhydrazine (DNP) and anti-DNP immunoblotting. Nine spots representing glycoproteins which showed enrichment or high specific oxidation indices in AD HepA-ConA 2-D gels relative to NEC samples were analyzed by matrix-assisted laser desorption-time of flight-mass spectrometry and identified with high probability (p < 0.001) as isoforms of human transferrin (Tf), hemopexin (Hpx) and alpha-1-antitrypsin (alpha-1-AT). These glycoproteins were concentrated, respectively, 5-, 6.5- and 107-fold in HepA-ConA eluates derived from AD plasma relative to the NEC samples. Specific oxidation indices of the identified Tf and Hpx isoforms in AD plasma were respectively, 7.4 and 2.8 relative to NEC. Our findings provide further evidence for systemic derangements in heme/iron/redox homeostasis and activation of the acute phase response in sporadic AD. Moreover, the data implicate isoforms of Tf, Hpx and alpha-1-AT as potential biological markers of this condition.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14595822     DOI: 10.1002/pmic.200300475

Source DB:  PubMed          Journal:  Proteomics        ISSN: 1615-9853            Impact factor:   3.984


  29 in total

Review 1.  Redox proteomics and amyloid β-peptide: insights into Alzheimer disease.

Authors:  D Allan Butterfield; Debra Boyd-Kimball
Journal:  J Neurochem       Date:  2018-11-27       Impact factor: 5.372

2.  Problems associated with biological markers of Alzheimer's disease.

Authors:  H J Frey; K M Mattila; M A Korolainen; T Pirttilä
Journal:  Neurochem Res       Date:  2005-12       Impact factor: 3.996

Review 3.  Two-dimensional protein electrophoresis: from molecular pathway discovery to biomarker discovery in neurological disorders.

Authors:  Leila H Choe; Brenda G Werner; Kelvin H Lee
Journal:  NeuroRx       Date:  2006-07

4.  Plasma alkaline phosphatase is elevated in Alzheimer's disease and inversely correlates with cognitive function.

Authors:  Katherine Ab Kellett; Jonathan Williams; Emma Rlc Vardy; A David Smith; Nigel M Hooper
Journal:  Int J Mol Epidemiol Genet       Date:  2011-02-10

5.  Additive effects of mitochondrion-targeted cytochrome CYP2E1 and alcohol toxicity on cytochrome c oxidase function and stability of respirosome complexes.

Authors:  Seema Bansal; Satish Srinivasan; Sureshkumar Anandasadagopan; Anindya Roy Chowdhury; Venkatesh Selvaraj; Balaraman Kalyanaraman; Joy Joseph; Narayan G Avadhani
Journal:  J Biol Chem       Date:  2012-03-06       Impact factor: 5.157

6.  Identification of oxidative modifications of hemopexin and their predicted physiological relevance.

Authors:  Peter Hahl; Rachel Hunt; Edward S Bjes; Andrew Skaff; Andrew Keightley; Ann Smith
Journal:  J Biol Chem       Date:  2017-06-08       Impact factor: 5.157

7.  Proteome expression and carbonylation changes during Trypanosoma cruzi infection and Chagas disease in rats.

Authors:  Jian-Jun Wen; Nisha Jain Garg
Journal:  Mol Cell Proteomics       Date:  2011-12-22       Impact factor: 5.911

8.  Biological markers and Alzheimer disease: a canadian perspective.

Authors:  Hyman M Schipper
Journal:  Int J Alzheimers Dis       Date:  2010-08-08

Review 9.  Peptides and proteins in plasma and cerebrospinal fluid as biomarkers for the prediction, diagnosis, and monitoring of therapeutic efficacy of Alzheimer's disease.

Authors:  Christopher D Aluise; Renã A Sowell; D Allan Butterfield
Journal:  Biochim Biophys Acta       Date:  2008-08-07

10.  Proteomics-derived cerebrospinal fluid markers of autopsy-confirmed Alzheimer's disease.

Authors:  Alex E Roher; Chera L Maarouf; Lucia I Sue; Yiran Hu; Jeffrey Wilson; Thomas G Beach
Journal:  Biomarkers       Date:  2009-11       Impact factor: 2.658

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.